To include your compound in the COVID-19 Resource Center, submit it here.

Novartis reports acromegaly data, earnings

Novartis AG (NYSE:NVS; SIX:NOVN) said pasireotide met the primary endpoint of normalization of IGF-1 and growth hormone levels vs. the pharma's Sandostatin LAR octreotide in a Phase III

Read the full 284 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE